If you follow peptide or metabolic research, you have probably seen the name retatrutide come up a lot. It is often described as a triple agonist, and that label confuses people who are used to hearing about GLP-1 compounds alone.
This guide explains retatrutide in plain English: what researchers mean by "triple agonist," how it fits next to dual-agonist compounds like tirzepatide, and what published studies have reported so far. Everything here is for laboratory research context only. Retatrutide sold through research suppliers is not an FDA-approved drug and is not for human or animal use.
What Is Retatrutide?
Retatrutide (development name LY3437943) is a synthetic peptide being studied as a single molecule that activates three hormone receptors involved in metabolic signaling:
- GLP-1 (glucagon-like peptide-1 receptor)
- GIP (glucose-dependent insulinotropic polypeptide receptor, also called gastric inhibitory polypeptide)
- Glucagon (glucagon receptor)
Think of it like a research compound designed to hit three related "switches" in metabolic pathways at once, instead of one or two. Pharmaceutical researchers study it as a once-weekly injectable peptide with a long half-life (published work has reported roughly six days), which supports weekly dosing in clinical trial designs.
Triple Agonist vs. Dual Agonist: Simple Comparison
Many readers already know tirzepatide as a dual agonist because it targets GLP-1 and GIP. Retatrutide adds glucagon receptor activity on top of those two pathways.
A simple way to picture the difference:
- Single-pathway research peptides: one main receptor focus
- Dual agonist (example: tirzepatide): GLP-1 + GIP
- Triple agonist (retatrutide): GLP-1 + GIP + glucagon
Why does that matter in the lab? Researchers use multi-receptor compounds to study how pathways interact. Metabolic signaling is not one isolated line. It is a network. Triple-agonist models let labs ask different questions than single- or dual-pathway tools alone.
What Published Research Has Reported
Retatrutide has been studied in controlled human trials run by pharmaceutical sponsors, not as an approved medicine. Key published findings include:
Phase 2 obesity trial (NEJM)
A widely cited Phase 2 trial in adults with obesity (without type 2 diabetes) reported meaningful weight change across dose groups over 48 weeks, with gastrointestinal side effects as the most common adverse events. That trial is a major reference point for how researchers talk about retatrutide's signal in metabolic studies.
Ongoing Phase 3 programs
The compound remains investigational. Drug developers have reported large Phase 3 programs (including the TRIUMPH trial series) studying obesity, type 2 diabetes, knee osteoarthritis pain, sleep apnea, and other metabolic endpoints. As of published company disclosures, retatrutide is not FDA-approved for any indication.
Systematic reviews
Independent reviewers have summarized randomized trial data and noted dose-related patterns in metabolic outcomes, while also emphasizing that long-term, real-world safety data still depend on completed Phase 3 results.
Important: Clinical trial results describe investigational drug programs. They do not mean research-grade retatrutide vials from a peptide supplier are safe or effective for people.
Why Labs Study Retatrutide
Research groups working with retatrutide typically focus on laboratory questions such as:
- Multi-receptor signaling models in metabolic pathways
- Comparing triple-agonist activity to dual-agonist reference compounds
- Receptor binding and pathway interaction experiments
- Analytical method development and batch characterization
That last point matters for buyers. If you are sourcing retatrutide for the lab, quality documentation matters as much as the compound name on the label. See our plain-English guide on reading a peptide COA before you order.
Retatrutide vs. Research-Grade Supply: What Buyers Should Know
Retatrutide you see in a research catalog is sold for in-vitro or laboratory research use only. It is not the same product as an investigational drug vial in a regulated clinical trial, and it is not a substitute for any prescription medicine.
Before ordering, check:
- COA per batch: purity, identity, and batch number match
- Proper storage: lyophilized peptides need cold, stable handling (see our storage guide)
- Research-only labeling: RUO products are for lab work, not consumption
CoreVials lists retatrutide for qualified research buyers with batch documentation when available. Browse the retatrutide product page for current sizes and stock status.
Common Questions
Is retatrutide the same as tirzepatide? No. Tirzepatide is studied as a dual agonist (GLP-1 and GIP). Retatrutide adds glucagon receptor activity and is studied as a triple agonist.
Is retatrutide FDA approved? No. Published trial data comes from investigational drug development programs. Research peptides sold online are not approved medicines.
Can I use retatrutide for weight loss? No. Research peptides are for laboratory research only and are not for human or animal consumption, medical use, or personal use of any kind.
Where can I read more on the science? Start with the Phase 2 publication in the New England Journal of Medicine, then review independent summaries in peer-reviewed journals. Our earlier post on triple-agonist research basics covers the lab-science angle in more depth.
Sources
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. NEJMoa2301972
- Systematic review and meta-analysis of retatrutide randomized trials. PMC12026077
- Review of triple-agonist obesity therapies. Current Cardiovascular Risk Reports (Springer)
- Eli Lilly investigational retatrutide Phase 3 disclosures. Lilly investor news
Research Use Only. Not for human or animal consumption.
